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The enzyme fatty acid amide hydrolase (FAAH) cata-
lyzes the in vivo degradation of the endocannabinoid
anandamide, thus controlling its action at receptors.
A novel FAAH inhibitor, AM3506, normalizes the
elevated blood pressure and cardiac contractility of
spontaneously hypertensive rats (SHR) without
affecting these parameters in normotensive rats.
These effects are due to blockade of FAAH and a cor-
responding rise in brain anandamide levels, resulting
in CB1 receptor-mediated decrease in sympathetic
tone. The supersensitivity of SHR to CB1 receptor-
mediated cardiovascular depression is related to
increased G protein coupling of CB1 receptors.
Importantly, AM3506 does not elicit hyperglycemia
and insulin resistance seen with other FAAH
inhibitors or in FAAH/ mice, which is related to its
inability to inhibit FAAH in the liver due to rapid
hepatic uptake and metabolism. This unique activity
profile offers improved therapeutic value in hyperten-
sion.
INTRODUCTION
Endocannabinoids are polyunsaturated fatty acid amides such
as arachidonoyl ethanolamide (anandamide) or esters such as
2-arachidonoyl glycerol (2-AG) that mobilize ‘‘on demand’’ and
signal through two Gi/o protein-coupled cannabinoid receptors
(Pacher et al., 2006): CB1 receptors, highly expressed in the brain
but also present at much lower yet functionally relevant concen-
trations in peripheral tissues, and CB2 receptors, expressed
predominantly in immune and hematopoietic cells (Howlett,
2005).
The concentration of endocannabinoids at target receptors is
tightly controlled by enzymes that generate and eliminate them.1256 Chemistry & Biology 17, 1256–1266, November 24, 2010 ª2010Anandamide is preferentially degraded in vivo by fatty acid
amide hydrolase (FAAH) (Cravatt et al., 1996), whereas 2-AG is
metabolized primarily by monoacylglyceride lipase (MAGL)
(Dinh et al., 2002), with additional involvement of ab-hydrolase
domain-containing 6 (ABHD6) (Marrs et al., 2010). Pharmacolog-
ical blockade or genetic ablation of FAAH in mice result in
elevated tissue levels of anandamide, as well as CB1 receptor-
mediated reductions in anxiety-like behavior (Kathuria et al.,
2003; Moreira et al., 2008), pain sensation (Cravatt et al.,
2001), and enhanced hypotensive responsiveness to exogenous
anandamide (Pacher et al., 2005). The FAAH inhibitor URB597
was also found to normalize blood pressure in rats with various
forms of hypertension by decreasing cardiac contractility and
total peripheral resistance through a CB1 receptor-mediated
mechanism (Batkai et al., 2004). In humans, higher anandamide
plasma levels have been linked to lower blood pressure in young
males with a functional FAAH gene variant (Sarzani et al., 2008)
that had been found to result in reduced enzymatic activity
(Chiang et al., 2004). FAAH deficiency also promotes excessive
energy storage and insulin resistance through a food intake-
independent mechanism (Tourino et al., 2010). Thus, a dynamic
relationship exists between endocannabinoid tone and cardio-
vascular and metabolic functions.
Here, we report the structure and pharmacological profile of
a highly potent and in vivo effective FAAH inhibitor, AM3506.
AM3506 is more potent than URB597 in reducing blood pres-
sure, heart rate, and cardiac contractility in hypertensive animals
through activation of CB1 receptors, which correlates with the
blockade of FAAH activity and the consequent increase in tissue
anandamide levels. The cardiovascular effects of AM3506 can
be attributed to central CB1 receptor-mediated reduction in
sympathetic tone, and the much greater responsiveness of
hypertensive compared with normotensive animals is related to
increased coupling of CB1 receptors to G proteins in the CNS
of the former. Finally, unlike URB597 which blocks FAAH in
both brain and liver and causes hyperglycemia in rats and
glucose intolerance in obese mice, AM3506 does not block
FAAH activity in liver and has no obvious effect on these
glycemic parameters.Elsevier Ltd All rights reserved
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Figure 1. Inhibition of FAAH Activity by
AM3506
(A) Activity-based protein profiling in mouse brain
(left) and liver (right), soluble (sol), and membrane
fractions (mem).
(B) Comparison of FAAH inhibition in mouse
brain (B, C) and liver (,, -) by AM3506
(open symbols) and URB597 (filled symbols),
as assessed by [3H]ethanolamine release from
[3H]anandamide.
(C) Effect of inhibitors on human recombinant
FAAH activity.
(D) Effect of AM3506 on human recombinant
MAGL activity. Values in (B)–(D) are mean ± SEM
from three to six experiments in triplicates.
(E) Chemical structure of FAAH inhibitors.
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Structure of AM3506
AM3506 (Figure 1E) is a hydroxyl substituted phenylalkylsulfonyl
fluoride (Deutsch et al., 1997) structurally related to the broad
spectrum serine protease inhibitor, phenyl methyl sulfonyl fluo-
ride (PMSF), but unrelated to the currently available in vivo effec-
tive FAAH inhibitors, such as the carbamate URB597 (Kathuria
et al., 2003) or the piperidine urea-based compounds (Ahn
et al., 2009).
FAAH Inhibitory Activity and Target Specificity
of AM3506
The effectiveness and target selectivity of AM3506 to inhibit
FAAH activity was tested using several approaches. First, mice
were treated with bolus i.p. doses of 0.1 or 1 mg/kg AM3506,
and the activity of serine hydrolases in brain tissue obtained after
1 hr was assayed using competitive activity-based protein
profiling (Leung et al., 2003). As illustrated in Figure 1A, treatment
of mice with 0.1 mg/kg AM3506 i.p. reduced brain FAAH activityChemistry & Biology 17, 1256–1266, November 24, 2010 ªwith no change in the activity of any of
a large number of other serine hydrolases
whereas at 1 mg/kg, AM3506 completely
blocked FAAH and partially inhibited
MAGL and ABHD6. Using the same tech-
nique, AM3506 had similarly low ‘‘off-
target’’ effects in the liver, with only
MAGL and an unidentified, 58 kDa
protein, showing partial inhibition at the
higher, 1 mg/kg dose. The effect of
AM3506 on hepatic FAAH could not be
assessed using this technique, due to
the presence of prominent interfering
proteins of similar molecular weight.
In the assay measuring the release of
[3H]ethanolamine from [3H] anandamide
(Figure 1B), AM3506 caused dose-
dependent inhibition of brain FAAH
activity (ID50 = 0.10 mg/kg). Surprisingly,
AM3506 was devoid of substantial
FAAH inhibitory activity in liver of the
same mice in doses up to 1 mg/kg. Incontrast, the reference compound URB597 had similar FAAH
inhibitory activity in liver (ID50 = 0.45 mg/kg) as in brain
(ID50 = 0.22 mg/kg).
Using this same assay, both AM3506 and URB597 were
fully effective orally and produced the same pattern of FAAH
inhibition as after parenteral administration. Thus, 1 mg/kg
AM3506 suppressed the enzyme in brain (by 90% ± 0.4%),
but had little effect on hepatic FAAH activity (by 13% ±
2.6%; n = 5), whereas 10 mg/kg URB597 equally suppressed
FAAH activity in brain (by 86% ± 2%) and liver (83% ± 0.5%;
n = 5). The duration of FAAH inhibition was also tested.
Following treatment with 1 mg/kg AM3506 i.p., FAAH was
inhibited by >99% for up to 2 hr, 90% at 12 hr and 80%
24 hr in agreement with the covalent nature of its interaction
with its target, as reported earlier for fluorosulfonates, PMSF
and some other fluorophosphonates (Seierstad and Breiten-
bucher, 2008).
The FAAH inhibitory activity of AM3506 and URB597 in vitro
was also tested against human recombinant FAAH (Figure 1C).
In this assay, AM3506 was twice as potent as URB597 (IC50s2010 Elsevier Ltd All rights reserved 1257
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Figure 2. Inverse Relationship between FAAH Activity and Ananda-
mide, but Not 2-AG, Levels in Brain Tissue Is Similar in SHR and
WKY Rats
Rats were treated with the indicated bolus i.p. doses of AM3506 and were
sacrificed 1 hr later tomeasure FAAH activity and anandamide and 2-AG levels
in brain tissue. Values are mean ± SEM from five to six experiments. *p < 0.05,
**p < 0.01 and ***p < 0.001, compared with vehicle (V).
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Antihypertensive Effect of Blocking FAAH in Brainof 48 and 118 nM, respectively), with PMSF being three orders of
magnitude less potent. AM3506 weakly inhibited human
recombinant MAGL with an IC50 of 11 mM (Figure 1D), for
a FAAH:MAGL potency ratio of >220-fold.
The assay based on the release of [3H]ethanolamine from
[3H]anandamide was used to quantify FAAH activity in SHR
and WKY brain (Figure 2). Basal FAAH activity was similar in
SHR (59.1 ± 0.8) and WKY (62.6 ± 1.1 fmol/mg/min, n = 3–5)
and was equally inhibited by AM3506, with ID50 values close to
0.1 mg/kg. The dose-dependent inhibition of FAAH by AM3506
was accompanied by parallel increases in brain anandamide
levels, whereas 2-AG levels remained unaffected by AM35061258 Chemistry & Biology 17, 1256–1266, November 24, 2010 ª2010(Figure 2). In a similar, ex vivoMAGL assaymeasuring the release
of [3H]glycerol from 2-oleoyl [3H]glycerol in brain homogenates of
mice treated 1 hr prior to sacrifice with vehicle versus different
i.p. doses of AM3506, no inhibition was observed at 0.3 and
1.0 mg/kg (5.2% ± 4.8% and 1.9% ± 4.8%, respectively,
n = 4 in each group), and moderate inhibition was observed
only after 3 mg/kg (38.8% ± 7.1%, n = 4). This indicates
> 30-fold in vivo selectivity for FAAH over MAGL and also that
the maximally effective in vivo dose of 1 mg/kg caused complete
inhibition of FAAH with no inhibition of MAGL.
AM3506 had low affinity for binding to CB1 (5.77mmol/liter) and
moderate affinity for CB2 receptors (192 nmol/liter), and did
not affect anandamide transport at concentrations up to
20 mmol/liter.
Cardiovascular Effects of AM3506 Are Mediated
by Endogenous Anandamide Acting via CB1 Receptors
In SHR, AM3506 (1 mg/kg i.v.) elicited a profound and sustained
decrease in MAP as well as marked bradycardia (Figure 3A),
whereas only slight changes in MAP and HR were observed in
WKY (Figure 3B). The effects of AM3506 in SHR were dose
dependent, with hypotensive and bradycardic ED50 values of
0.14 and 0.10 mg/kg, respectively, whereas URB597 was
40 times less potent, with corresponding ED50 values of 5.2
and 4.0 mg/kg. The effects of AM3506 were prevented by
pretreatment with the CB1 antagonist AM251, which also acutely
reversed the fully developed effects (Figure 3A). Similar acute
reversal was elicited by the CB1 antagonist rimonabant
(3 mg/kg, DMBP: +101 ± 9 mmHg; DHR: +129 ± 14 bpm), but
not by a novel, peripherally restricted CB1 antagonist, AM6545
(Figure 3A).
AM3506 (0.5 mg/kg i.v.) also caused hypotension and brady-
cardia in awake, chronically cannulated SHR. Peak decreases
in MAP and HR were from 172 ± 4 to 128 ± 5 mmHg
(p < 0.001, n = 5) and from 345 ± 10 to 290 ± 15 bpm
(p < 0.05), respectively, and the effects lasted up to 60 min.
As shown in Figure 4A, 1 mg/kg AM3506 caused a marked
decrease in cardiac contractility in SHR, as assessed by the
end-systolic pressure-volume relation (ESPVR), a load-indepen-
dent indicator of systolic contractility (Kass et al., 1987), as well
as by decreases in left ventricular end-systolic pressure (LVESP)
(Figure 4B) and dP/dtmax (Figure 4C), total peripheral resistance
(TPR) (Figure 4D) and cardiac output (CO) (Figure 4E). No
changes of these parameters were observed in normotensive
WKY rats (Figures 4B–4E).
Cardiovascular Effects of AM3506 Depend
on Autonomic Nervous Tone
To test whether the effects of AM3506 aremediated via the auto-
nomic nervous system, autonomic tone was disrupted by gangli-
onic blockade. Treatment of SHR with hexamethonium (C6,
20 mg/kg i.v) caused a profound drop in MAP and HR, which
were then restored to the preexisting baseline by continuous
infusion of vasopressin and isoproterenol, respectively.
Blockade of autonomic tone was verified by the near-complete
loss of reflex tachycardia or bradycardia in response to bolus
injections of sodium nitroprusside or phenylephrine, respec-
tively. In such animals, the hypotension and bradycardia elicited
by 1 mg/kg AM3506 were reduced by 89.6% ± 3.6% andElsevier Ltd All rights reserved
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in Anaesthetized SHR Are Mediated by CB1
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Solid arrows indicate the i.v. injection to SHR (A)
and WKY (B) of vehicle (B), 1 mg/kg AM3506
(C), and 1 mg/kg AM3506 following i.p. injection
of 3mg/kg AM251 60min earlier (-). Open arrows
indicate the i.v. injection of 3 mg/kg AM251 (-) or
3 mg/kg AM6545 (A) to a separate group of SHR,
at the peak hypotensive response to AM3506.
Values of MAP and HR are mean ± SEM from
four to eight experiments.
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Antihypertensive Effect of Blocking FAAH in Brain74.0%± 7.7%, respectively (Figure 5A) (n = 5-13; p < 0.001), indi-
cating the dependence of these effects on intact autonomic
tone. As a further indication that AM3506 decreases sympathetic
tone, plasma norepinephrine levels in anesthetized SHR were
reduced by 82% ± 5%, from 311 ± 41 to 53 ± 12 pg/ml (n = 5,
p < 0.01) 30 min after the i.v. administration of 1 mg/kg
AM3506. In WKY, baseline plasma norepinephrine was lower
than in SHR (198 ± 11 pg/ml, p < 0.05) and remained unaffected
by AM3506 (167 ± 35 pg/ml, p > 0.2, n = 3).
Increased Cardiovascular Responsiveness
of Hypertensive Rats to CB1 Receptor Activation
The greater depressor responses to AM3506 in SHR versusWKY
despite similar degree of FAAH inhibition and rise in brain anan-
damide suggest increased target-tissue responsiveness to CB1
receptor activation in SHR. Indeed, the cannabinoid agonist
HU210 also elicited much greater hypotension in SHR than in
WKY (Figure 5B). In both strains, the effects of HU210 were abol-
ished by AM251 or by ganglionic blockade, indicating the
involvement of neuronal CB1 receptors.
The sympathoinhibitory effects of HU210 or AM3506 may be
triggered in the CNS or at presynaptic CB1 receptors on
postganglionic sympathetic nerve terminals in the heart and
vasculature. To distinguish between these possibilities, we
tested the cardiovascular effects of a nonbrain penetrant
CB1/CB2 mixed agonist, CB13 (Dziadulewicz et al., 2007). The
hypotensive effect of 0.3 mg/kg CB13 was similar in SHR and
WKY (40 ± 6 versus 36 ± 10 mmHg), suggesting that the
increased hypotensive effectiveness of HU210 in SHR is due
to a central mechanism.Chemistry & Biology 17, 1256–1266, November 24, 2010 ªIncreased Efficiency of CB1
Receptor Coupling in SHR
The increased responsiveness of SHR to
direct activation of CB1 receptors sug-
gested increased expression and/or
increased coupling efficiency of CB1
receptors. CB1 receptor density, as
quantified by [3H]-rimonabant binding,
was similar in WKY and SHR brain
(1.58 ± 0.16 versus 1.60 ± 0.06 pmol/mg
protein, respectively), with slightly higher
affinity for the radioligand in SHR
(0.71 ± 0.09 nmol/liter) than in WKY
(1.92 ± 0.53 nmol/liter). However, CB1
receptor coupling efficiency, as deducedfrom HU210-stimulated GTPgS labeling, was dramatically
increased in brain membrane preparations from SHR versus
WKY (Figure 5C).
Hepatic FAAH Is Not Inhibited by AM3506 Due
to Its Rapid Hepatic Metabolism
Following in vivo administration, a maximally effective dose of
AM3506 (1 mg/kg i.p.) blocked FAAH activity in brain but not in
liver, whereas an equimolar dose of URB597 (1.38 mg/kg i.p.)
blocked FAAH activity equally in both tissues (Figure 6A). In
contrast, when the compounds were added in vitro to tissue
homogenates at a concentration of 100 nM, they were both
equally effective in blocking FAAH activity in brain and liver (Fig-
ure 6B). This suggests that the ability of AM3506 to block FAAH is
similar in brain and liver, but the uptake and metabolism of
AM3506 by intact hepatocytes is rapid enough to prevent its
access to FAAH.
To further explore this possibility, we incubated hepatocyte
suspensions of different cell density with a fixed concentration
(100 nM) of AM3506 or URB597 versus vehicle for 30 min, and
measured FAAH activity in the cell pellet (Figure 6C). In a dilute
suspension of hepatocytes (1 mg wet cell weight/ml medium),
both AM3506 and URB597 nearly completely blocked FAAH,
similar to what was observed in cell-free homogenates. When
free drug was measured as the parent ion in the cell-free super-
natant, 50%–55%of the drug added at 0min was still present for
both AM3506 and URB597 at 10 min. In contrast, in dense
suspensions of hepatocytes (40 mg/ml), URB597, but not
AM3506 blocked FAAH activity, which replicates the findings in
intact animals. Further analysis of such preparations indicated2010 Elsevier Ltd All rights reserved 1259
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Figure 4. Hemodynamic Effects of AM3506 in Anesthetized SHR and
WKY Rats
Anesthetized rats were instrumented with an intraventricular pressure/volume
microcatheter system for measurement of (A) end-systolic pressure-volume
relations (ESPVR); (B) left ventricular end-systolic pressure (LVESP); (C)
dP/dtmax; (D) total peripheral resistance (TPR); and (E) cardiac output (CO).
Effects of vehicle (, open columns) and 1 mg/kg AM3506 (+, filled columns)
are shown. (A) illustrates real-time pressure-volume loops recorded in a single
SHR, whereas values in (B)–(E) are mean ± SEM from six to eight experiments.
*p < 0.05 compared with vehicle.
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ure 6D, left panel). In the cell pellets, URB597 levels gradually
declined over 10 min, whereas AM3506 levels were below
threshold immediately after the addition of the drug and re-
mained undetectable for the remaining incubation period (Fig-
ure 6D, second panel from left). In these experiments, the
0 min time point did include the time needed to separate the
pellet (1 min of centrifugation at 0C). FAAH activity was rapidly
and nearly completely blocked in the URB597-exposed cells,
whereas there was no measurable change in FAAH activity in
AM3506-incubated cells (Figure 6D, third panel from left).
Parallel to FAAH activity, anandamide levels in hepatocytes
were markedly increased by URB597, but remained unchanged1260 Chemistry & Biology 17, 1256–1266, November 24, 2010 ª2010by AM3506 (Figure 6D, right panel). The recovery of both drugs
from cell-free medium remained constant from 0 to 30 min, so
spontaneous degradation could not account for their time-
dependent loss in the presence of hepatocytes.
Blockade of Hepatic FAAH by URB597 Results
in Glucose Intolerance in Obese Mice
High-fat diet (HFD)-induced obesity (DIO) is associated with
increased activity of the hepatic endocannabinoid/CB1 receptor
system, which contributes to obesity-related glucose intoler-
ance/insulin resistance (Osei-Hyiaman et al., 2008). We tested
whether acute treatment with FAAH inhibitors can influence gly-
cemic control in DIO mice. As illustrated in Figure 7A, treatment
of male DIO mice with 1 mg/kg AM3506 did not affect glucose
tolerance, as tested using the i.p. glucose tolerance test,
whereas an equimolar dose of URB597 (1.38 mg/kg) resulted
in a marked increase in glucose intolerance, even though it
was much less effective in producing hypotension. Similar treat-
ment with URB597 failed to affect glucose tolerance in liver-
specific CB1
/ mice on HFD (Figure 7B). Increasing the dose
of URB597 to 10 mg/kg, which is equieffective with 1 mg/kg
AM3506 in causing hypotension, caused the same degree of
glucose intolerance in wild-type mice on HFD as the lower
dose, and it remained ineffective in liver-specific CB1
/ mice
on HFD (not shown). These findings indicate that blockade of
FAAH in liver results in hepatic CB1 receptor-mediated increase
in glucose intolerance.
URB597 (10 mg/kg i.p.) also increased nonfasting blood
glucose in both SHR (from 104.0 ± 7.4 to 144.0 ± 9.6 mg/dl,
n = 4, p < 0.05) and WKY (from 90.0 ± 7.2 to 135.3 ±
12.9 mg/dl, n = 4, p < 0.05), whereas AM3506, 1 mg/kg i.p.,
had no such effect (SHR: 97.8 ± 5.6 to 96.8 ± 2.9, n = 6; WKY:
114.5 ± 5.3 to 108.2 ± 4.5, n = 6). In the same rats, 10 mg/kg
URB597 blocked hepatic FAAH activity by 93.1% ± 0.3% in
SHR and 92.6% ± 0.2% in WKY, whereas 1 mg/kg AM3506
only marginally reduced it, by 11.1% ± 0.4% in SHR and
6.7% ± 0.2% in WKY (n = 3–5).
DISCUSSION
Here, we report the unique activity profile of a highly potent and
in vivo effective FAAH inhibitor, AM3506. Similar to another
FAAH inhibitor, URB597, AM3506 reverses the increased blood
pressure and cardiac contractility of hypertensive rats without
causing similar effects in normotensive rats. These effects could
be attributed to sympathoinhibition mediated indirectly by
endogenous anandamide acting at CB1 receptors in the central
nervous system. Unlike the other FAAH inhibitor, AM3506 does
not inhibit FAAH activity in the liver and does not elicit hypergly-
cemia and insulin resistance seen after global inhibition or
genetic ablation of FAAH, thus offering an improved therapeutic
profile as a potential antihypertensive agent.
AM3506 is structurally unrelated to currently available FAAH
inhibitors, and is a close structural analog of the serine protease
inhibitor PMSF. The original observation that PMSF prolonged
the half-life of anandamide and increased its apparent affinity
for CB1 receptors in membrane preparations was the first
evidence supporting the existence of an endogenous amidase
being involved in the in vivo biodegradation of anandamideElsevier Ltd All rights reserved
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Figure 5. Neuronal CB1 Receptor Coupling to G Proteins Is Increased in Hypertension
Abolus i.v. dose of 1mg/kg AM3506 (A) or 1 mg/kg HU210 (B) was injected to anaesthetized control SHR (open columns) or SHR receiving hexamethonium+vaso-
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receptors in membrane preparations from whole brain of SHR and WKY rats was assessed by measuring HU210-induced increases in GTPgS labeling, as
described in Methods. Values are mean ± SEM from four experiments in triplicates. *p < 0.05 compared with WKY rats.
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AM374, an early-generation FAAH inhibitor based on the PMSF
structure (Deutsch et al., 1997; Janero et al., 2009; Lu et al.,
2006), led to AM3506, a sulfonyl fluoride analog with enhanced
affinity and favorable oral bioavailability and brain penetrability.
AM3506 is selective for FAAH over MAGL, the maximally effec-
tive in vivo dose of 1 mg/kg causing 100% inhibition of FAAH
with no inhibition of MAGL, as verified using ex vivo enzyme
activity assays.
Earlier observations indicated that the endocannabinoid
system remains quiescent under normotensive conditions, but
becomes activated in various experimental models of hyperten-
sion as a compensatory mechanism (Batkai et al., 2004). This
allows for the use of SHR as a model to study the cardiovascular
consequences ofmodulating the activity of the endocannabinoid
system (Batkai et al., 2004). AM3506 caused strong cardiovas-
cular depression in SHR and only modest hypotension and
bradycardia in normotensive WKY rats. While these effects are
similar to the earlier reported effects of the reference FAAH
antagonist URB597 (Batkai et al., 2004), they expand those find-
ings in several ways.
First, ganglionic blockade combined with restoration of base-
line vascular tone and heart rate resulted in a near complete loss
of the hypotensive and bradycardic responses to AM3506 in
SHR. These findings make it unlikely that modest increases in
CB1 receptor expression in heart and aortic smooth muscle of
SHR compared with WKY rats, as reported earlier (Batkai
et al., 2004), could account for the increased responsiveness
of SHR to CB1 receptor activation, and indicate the dominantChemistry & Biology 17, 1256–126role of neuronal CB1 receptors. Reduction of sympathetic tone
in SHR by AM3506 is further indicated by the marked reduction
in plasma norepinephrine. This could result from a centrally trig-
gered reduction in sympathetic outflow, or from activation of
presynaptic CB1 receptors located at sympathetic nerve termi-
nals in the heart and vasculature (Varga et al., 1996). The former
mechanism is favored, however, by the observation that the
cardiovascular depressor response to AM3506 could be
reversed by both rimonabant and AM251, brain-penetrant CB1
antagonists, but not by AM6545, a novel, peripherally restricted
CB1 antagonist (Tam et al., 2010). Furthermore, the moderate
hypotensive effect of a peripherally restricted cannabinoid
agonist was similar in SHR and WKY.
Second, there are both quantitative and qualitative differences
between the FAAH inhibitory actions of AM3506 and URB597.
AM3506 is more potent than URB597 in reducing blood pressure
and heart rate as well as in inhibiting FAAH activity in brain, and
its effects are much longer lasting. Unexpectedly, AM3506 failed
to inhibit FAAH in the liver, whereas URB597 inhibited FAAHwith
similar potency and efficacy in brain and liver. A plausible reason
for the lack of effect of AM3506 in the liver is its rapid uptake and
metabolism by hepatocytes. Due to the covalent binding of
AM3506 to its target, it is not possible to quantitatively analyze
its metabolic fate in intact cells. Instead, we used the approach
of varying the ratio of liver tissue to drug in suspensions of iso-
lated hepatocytes as a way explore the effect of cellular uptake
and metabolism on the pharmacological action of a compound
(Kunos, 1984). In dilute suspensions of hepatocytes, the
capacity of the liver to eliminate AM3506 was not sufficient to6, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1261
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Figure 6. Selective Resistance of Hepatic FAAH to Inhibition by AM3506 In Vivo Is Related toRapid Uptake andDegradation of AM3506 by the
Liver
(A) FAAH activity in brain and liver 1 hr following in vivo treatment of mice with 1 mg/kg AM3506 or 1.38 mg/kg URB597.
(B) FAAH activity following in vitro incubation of brain or liver homogenates with 100 nM AM3506 or URB597.
(C) FAAH activity in cell pellets following incubation of dilute (1 mg cells/ml) or dense hepatocyte suspensions (40 mg cells/ml) with 100 nM AM3506 or URB597.
(D) Analysis of the fate and activity of AM3506 andURB597 in dense suspension of hepatocytes. Drugs or vehicle were added to hepatocyte suspensions at 0min.
At the indicated times, cells were rapidly centrifuged, and drug levels were determined in the cell-free supernatant (left) or pellet (second from left). The pellet
was also used to determine FAAH activity (third from left) and anandamide levels (right). Each point represents the means from four to five separate experiments.
*p < 0.05, **p < 0.01 relative to corresponding 0 min value. For explanations, see text.
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Antihypertensive Effect of Blocking FAAH in Brainprevent its access to and inhibition of FAAH. However, in a much
more dense suspension of cells, which approximates the condi-
tions in the intact liver, AM3506 was taken up and metabolized
very rapidly, which prevented its ability to reach and block
FAAH (Figure 6D). URB597 was eliminated more slowly, and as
a result it was able to fully block FAAHwith the resulting increase
in hepatic anandamide (Figure 6D).
Formation of adducts of AM3506 with small molecules, as re-
ported for PMSF (Fontana et al., 1995), is unlikely to account for
its lack of inhibition of FAAH in the liver, as AM3506 was able to
fully block FAAH in the brain or in cell-free extracts of liver.
Furthermore, interaction with ‘‘off-target’’ serine proteases in
liver is also unlikely to explain the lack of FAAH inhibition,
because AM3506 had fewer such targets (Figure 1A) than did1262 Chemistry & Biology 17, 1256–1266, November 24, 2010 ª2010URB597 (see Figure 8 in Ahn et al., 2007), yet URB597 was
able to block hepatic FAAH.
The lack of in vivo effect of AM3506 on hepatic FAAH turns out
to be an advantageous feature, as the development of diet-
induced fatty liver and insulin resistance have been linked to inhi-
bition of FAAH activity in the liver and the resulting increase in
hepatic anandamide levels (Osei-Hyiaman et al., 2005, 2008;
Tam et al., 2010). The predisposition of FAAH-deficient mice to
diet-induced hyperglycemia and insulin resistance (Tourino
et al., 2010) also supports this possibility. Indeed, URB597, but
not AM3506, caused hyperglycemia in both SHR and WKY.
Furthermore, URB597 even at a subhypotensive dose caused
glucose intolerance in mice with diet-induced obesity, whereas
an equimolar dose of AM3506, which elicited pronouncedElsevier Ltd All rights reserved
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Figure 7. URB597, but Not AM3506, Increases Glucose Intolerance
in Mice with Diet-Induced Obesity
(A) Male mice kept on a high-fat diet for 14 weeks were subjected to an intra-
peritoneal glucose tolerance test (ipGTT) 60 min following the i.p. injection of
vehicle, 1.38 mg/kg URB597, or 1 mg/kg AM3506, as described in Experi-
mental Procedures. Area under the curve (AUC, mg hr/dl): 352 ± 28 (vehicle),
570 ± 45* (URB597), 411 ± 35 (AM3506). *p < 0.01 relative to value in vehicle
treated mice; n = 12–14 mice in each group.
(B) Liver-specific CB1 knockout (LCB1
/) mice subjected to ipGTT following
vehicle or URB597 treatment. AUC: 322 ± 37 (vehicle) versus 337 ± 14
(URB597), p > 0.5, n = 4. 8.
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Antihypertensive Effect of Blocking FAAH in Brainhypotension, caused no change in glucose tolerance. The
absence of a similar effect of URB597 in hepatocyte-specific
CB1 knockout mice indicates that this effect is likely mediated
by anandamide acting via hepatic CB1 receptors (Figure 7B).
Unlike in heart and aorta, CB1 receptor expression in the SHR
brain is not increased. Instead, there was a marked increase in
CB1 stimulated GTPgS binding in SHR compared with WKY
brain tissue, indicating enhanced G protein activation. CB1
receptors are coupled to Gi/Go proteins, and upregulation of
Gia protein isoforms has been documented in the heart and
vasculature of rats with different forms of hypertension, including
SHR (Ge et al., 2006; Kost et al., 1999; Marcil et al., 1997, 1998).
A similar mechanism in the brain may account for the enhanced
cardiovascular responsiveness of hypertensive animals to CB1
receptor activation. Nevertheless, a small contribution of
vascular and cardiac CB1 receptors is likely in view of the
significant hypotensive response to the peripherally restricted
CB receptor agonist, CB13. The fact that CB13 produced
a moderate hypotensive effect in SHR and WKY also suggests
that peripheral CB1 receptors are functional and may be subject
for modulation in certain cardiovascular pathologies.
The location in the brain of CB1 receptors mediating cardio-
vascular depressor responses is unclear. Microinjection of anan-
damide or an anandamide uptake inhibitor into the brainstem
nucleus of the solitary tract (NTS) of anesthetized normotensive
rats was found to enhance the baroreflex inhibition of renal
sympathetic nerve activity, an effect prevented by rimonabant,
and increases in blood pressure resulted in enhanced ananda-
mide content in the NTS (Seagard et al., 2004). However,
cannabinoids microinjected into the NTS caused less sympa-
thoinhibition in SHR than in normotensive rats (Brozoski et al.,
2009), which is evidence against the NTS being the site of the
antihypertensive effect of CB1 receptor activation. Another
potential site is the rostral ventrolateral medulla, the location of
premotor sympathetic neurons. It has been reported that micro-Chemistry & Biology 17, 1256–126injection of the synthetic cannabinoid agonist WIN55,212-2 into
this site elicits hypotension in normotensive rats, whereas similar
microinjection into the NTS had no effect on blood pressure (Nie-
derhoffer et al., 2003). The core central sympathetic network can
also be regulated at hypothalamic nuclei, circumventricular
organs, and area postrema (Guyenet, 2006). Further studies
are needed to identify the CNS location of CB1 receptors that
mediate the enhanced cardiodepressor response to endoge-
nous anandamide in SHR.
SIGNIFICANCE
The findings in this study provide an impetus to the use of
FAAH inhibitors to treat hypertension. First, the absence of
cardiovascular effects under normotensive conditions
would minimize unwanted side effects, such as orthostatic
hypotension. Second, FAAH inhibitors produce significant
antianxiety effects in rodents (Kathuria et al., 2003), which
may provide added benefit in neurogenic hypertension. At
the same time, behavioral effects that predict addictive
potential, such as catalepsy, are not amplified by FAAH inhi-
bition (Justinova et al., 2008; Kathuria et al., 2003), an impor-
tant safety consideration. Third, a major component of the
antihypertensive action of AM3506, similar to the previously
reported effect of URB597 (Batkai et al., 2004), is the marked
reduction of the inappropriately increased cardiac contrac-
tility. This suggests that chronic inhibition of FAAH may
not only normalize blood pressure but also mitigate the
development of the associated cardiac hypertrophy, an
independent risk factor for cardiovascular events and
mortality. Finally, the distinctive pharmacological profile of
AM3506 suggests a broader safety spectrum, especially
with regard to absence of mechanism-based metabolic
effects, which should make it attractive for potential thera-
peutic use as an antihypertensive in obese subjects.
EXPERIMENTAL PROCEDURES
Animals
Male 12- to 16-week-old spontaneously hypertensive rats (SHR) and age-
matchedWistar Kyoto (WKY) rats were obtained from Charles River Laborato-
ries; male C57Bl/6J mice were from Jackson Laboratories. Liver-specific
CB1
–/– mice were generated as described (Osei-Hyiaman et al., 2008). Exper-
imental protocols were in accordance with the ethical guidelines for animal
research and approved by the Institutional Animal Care and Use Committee
of NIAAA.
General Surgical Procedures
Rats were anesthetized with isoflurane via a nose cone (induced with 3%–4%
and followed by 1.5% in pure oxygen). Adequacy of anesthesia was verified by
the absence of tail-flick reflex. Animals were placed on a controlled heating
pad and core body temperature, measured by a rectal probe, was maintained
at 37C. For experiments in conscious animals, rats were implanted with
indwelling catheters in the femoral artery and femoral vein, as described earlier
(Lake et al., 1997), and allowed to recover. For other experiments, rats re-
mained anesthetized and instrumented as described (Batkai et al., 2004). In
brief, a left femoral artery was cannulated and the catheter connected to
a pressure transducer (Abbott Park, IL) for monitoring mean arterial pressure
(MAP). Heart rate (HR) was derived from the pressure wave. Signals were
amplified through a 13-4615-71 Differentiator Plug-in Module (Brush-Gould)
and recorded on PowerLab 4/30 data acquisition system (AD Instruments).
Left femoral vein was cannulated for i.v. bolus injection of drugs in a volume6, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1263
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drug infusion by means of a multichannel syringe pump (KD Scientific) and
right carotid artery was catheterized for blood withdrawal. Mean arterial pres-
sure (MAP) and heart rate (HR) were recorded. After 20 min stabilization,
animals received a bolus intravenous (i.v.) dose of FAAH antagonist, HU210
or vehicle andmean arterial pressure (MAP) and heart rate (HR) were recorded.
In some experiments, CB1 antagonist was injected i.p. 60 min before experi-
ment or i.v. at the peak of the hypotensive response to AM3506.
Autonomic Blockade
Ganglionic blockade was achieved with hexamethonium, as described
(Schreihofer et al., 2007). In brief, a bolus of 20 mg/kg hexamethonium was in-
jected i.v., followed by a continuousmaintenance infusion of 4mg/kg/hr. Vaso-
pressin (0.04–0.4 IU/kg/hr) and/or isoproterenol (0.3–0.5 mg/kg/hr) were also
infused to offset the hexamethonium-induced fall in basal MAP and HR,
respectively. Blockade of the autonomic nervous system was verified using
the phenylephrine/sodium nitroprusside sensitivity test (Schreihofer et al.,
2007). The baroreflex was quantified as a change HR/MAP ratio in response
to phenylephrine or sodium nitroprusside.
Hemodynamic Analyses
Cardiac contractility was assessed in anaesthetized rats by a pressure-volume
microcatheter system (Millar Instruments) as described (Batkai et al., 2004;
Pacher et al., 2008). In brief, a microtip pressure-volume catheter (SPR-838;
Millar Instruments) was inserted into the right carotid artery and advanced
into the left ventricle (LV) under pressure control. Signals were continuously re-
corded with an ARIA pressure-volume (PV) conductance system (Millar Instru-
ments) coupled to a Powerlab/4SP A/D converter (AD Instruments), stored,
and displayed on a computer. After stabilization for 20 min, AM3506
1 mg/kg or vehicle was injected i.v. and cardiac hemodynamic parameters
were recorded 20min later and computed using a cardiac PV analysis program
(PVAN2.9; Millar). Maximal pressure developed by the ventricle at any given
left ventricular volume was defined as the end-systolic pressure-volume rela-
tionship (ESPVR) and represented the inotropic state of the ventricle. Cardiac
output (CO) was calculated and corrected according to in vitro and in vivo
volume calibrations with PVAN2.9 and normalized to body weight (cardiac
index). The maximal slope of systolic pressure increment (+dP/dtmax) was
a time derivative of left ventricular pressure used as a cardiac contractility
parameter. Total peripheral resistance (TPR) was calculated as MAP/CO.
Catecholamine Assay
Blood was collected from left carotid artery before and after i.v. injection of
1 mg/kg AM506 and plasma norepinephrine levels were determined by liquid
chromatography with electrochemical detection, as described (Eisenhofer
et al., 1986).
FAAH and MAGL Activity
Antagonists were tested using inhibitor screening kits (Cayman Chemical Co.),
based on the release of a fluorophore from a synthetic substrate by recombi-
nant human FAAH andMAGL. AM3506 was also tested ex vivo using compet-
itive Activity-Based Protein Profiling (Leung et al., 2003) or the release of
[3H]ethanolamine from [3H]anandamide for FAAH inhibition (Fowler et al.,
2000), or the release of [3H]glycerol from 2-oleoyl-[3H]glycerol in the presence
of 1 mMURB597 for MAGL inhibitory activity (Dinh et al., 2002). Drug or vehicle
was injected i.p. or given by gavage and enzyme activity was determined in
harvested tissues. In some experiments, FAAH activity was measured in brain
and liver homogenates, adjusting the protein levels to yield equal amounts of
FAAH in the assay (10 mg protein for brain and 3 mg for liver to compensate for
the higher FAAH expression in liver).
Endocannabinoid Tissue Levels
Endocannabinoids were extracted and quantified using liquid chromatog-
raphy/in-line mass spectrometry, as described (Batkai et al., 2004). [2H4]anan-
damide was used as internal standard.
Isolation and Treatment of hepatocytes
Mouse hepatocytes were isolated by in situ liver perfusion with Collagenase
type I (Sigma-Aldrich) and Percoll (GE Healthcare) density gradient centrifuga-1264 Chemistry & Biology 17, 1256–1266, November 24, 2010 ª2010tion as described (Osei-Hyiaman et al., 2008). Hepatocytes were then resus-
pended in DMEM medium, containing 10% fetal bovine serum and L-gluta-
mine (Invitrogen). Concentrated (40 mg of wet cell weight per milliliter of
medium) and dilute (1 mg/ml) hepatocyte suspensions were prepared and
incubated with AM3506, URB597 (each 100 nM) or vehicle (DMSO;
1:1000 v/v) at 37C. Aliquots were removed at the indicated time points,
quickly chilled on ice and centrifuged at 400 3 g, 4C for 5 min. Drugs were
extracted from supernatant and hepatocyte pellets using the same protocol
as for endocannabinoids.
Measurement of Drug Levels by LC/MS/MS
Drugs were quantified by LC-MS/MS using an Agilent 6410 triple quadrupole
mass spectrometer (Agilent Technologies, USA) coupled with an Agilent 1200
LC system (Agilent Technologies, Germany). Liquid chromatographic separa-
tion was obtained using 2.5 ml injections of samples onto a Zorbax SB-C18
rapid resolution HT column (2.1 3 50 mm, 1.8 mm) from Agilent Technologies.
The autosampler was set at 4C and the column was maintained at 34C
during the analysis. Gradient elution mobile phases consisted of A (0.1% for-
mic acid in water) and B (0.1% formic acid in methanol). Gradient elution
(250 ml/min) began and was held at 10% B for the first 0.5 min, followed by
a linear increase toward 85% B at 1 min; this was maintained until 12.5 min
and then increased linearly to 100% B at 13 min; this was maintained until
14.5 min. At minute 16, the gradient changed linear to the initial setting which
was maintained for 6 min. The mass spectrometer was set for ESI in positive
ion mode. The source parameters were as follows; capillary voltage, 4000 V;
gas temperature, 350C; drying gas, 10 liter/min; nitrogen was used as the
nebulizing gas with a pressure of 40 psig. Collision-induced dissociation
(CID) was induced using nitrogen. Levels of each compound were analyzed
by multiple reactions monitoring (MRM). Mass spectrometric conditions
were optimized for AM3506, URB597, [2H4]AEA, and AEA with injection of
synthetic standards of each compound by using MassHunter Workstation
Optimizer software (Agilent Technologies, USA). The molecular ion and frag-
ments for each compound measured were as follows: m/z 247.1/107.0
and 247.1/77.1 for AM3506 (CID-energy: 12 V and 52 V, respectively), m/z
339.2/214.1 and 339.2/197.1 for URB597 (CID-energy: 8 V and 20 V,
respectively), m/z 352.3/66.1 and 352.3/91 for [2H4]AEA (CID-energy:
12 V and 56 V, respectively) and m/z 348.3/62.1 and 348.3/91 for AEA
(CID-energy: 12 V and 48 V, respectively). The acquisition and quantitation
of analytes were achieved usingMassHunterWorkstation LC/QQQAcquisition
and MassHunter Workstation Quantitative Analysis softwares, respectively
(Agilent Technologies, USA). Calibration curves were produced by using
synthetic AEA, URB597, and AM3506. The amounts of AEA and AM3506 in
the samples were determined by using linear regression of standard curves,
whereas URB597 was determined by using quadratic regression of standard
curve. Each time point represents hepatocytes pulled from three to four
animals measured in duplicates. The limit of detection for AM3506 and
URB597 was 1 pmol per injection.
CB1 and CB2 Receptor Binding and Anandamide Transport Assays
The affinity of AM3506 for CB1 and CB2 receptors was tested in radioligand
displacement assays, using [3H]CP,55940 as the radioligand and membrane
preparations from rat forebrain and spleen, respectively, as describe (Janero
et al., 2009; Lu et al., 2006). The effect of AM3506 on anandamide transport
was assessed by measuring its ability to inhibit [3H]anandamide uptake by
cultured CCF-STTG1 astrocytoma cells, as described (Fegley et al., 2004).
[35S]GTPgS Binding
Basal and agonist-stimulated [35S]GTPgS binding wasmeasured as described
(Tam et al., 2010).
Glucose Tolerance Test
MaleC57Bl6/Jmice, wild-type or LCB1
/, were kept on a diet containing 60%
of calories as fat (Research Diets Inc) for 14 weeks, by which time both strains
have become fat due to increased adipose mass. Mice were then fasted over-
night, followed by an i.p. injection of vehicle, 10 mg/kg URB597 or 1 mg/kg
AM3506. Sixty minutes later the mice received 1.5 g/kg glucose i.p. and blood
glucose levels were monitored for 2 hr, as described (Osei-Hyiaman et al.,
2008).Elsevier Ltd All rights reserved
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URB597 was from Cayman; AM251, HU210, and CB13 were from Tocris
Bioscience; rimonabant was provided by the NIDA Drug Supply program.
[3H]anandamide and 2-oleoyl [3H]glycerol were from American Radiolabeled
Chemicals. All other chemicals were from Sigma-Aldrich. AM3506 (5-[4-hy-
droxyphenyl]pentanesulfonyl fluoride) was synthesized in nine steps starting
from commercially available 4-phenoxybutyl bromide and 4-anisaldehyde.
Details of the synthesis along with a full structure-activity relationship study
involving closely related analogs will be published elsewhere.
AM3506, URB597, CB13, rimonabant, AM251, and AM6545 were dissolved
in DMSO, Tween 80 and saline (1:1:18). For gavage, AM3506 and URB597
were dissolved in DMSO and corn oil (1:19). HU210 was dissolved in DMSO
and saline (1:19). All other drugs were dissolved in saline.
Data Analysis
Statistical analyses were performed using Prism 4 (GraphPad). t test for
unpaired or paired data was used for comparison of values between two
groups and one-way ANOVA followed by Dunnett’s test was used for compar-
ison of multiple independent groups. When several variables were considered,
two-way ANOVA with Bonferroni’s post-hoc test was applied. Differences
were considered significant when p < 0.05. Values were presented as
mean ± SEM).
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